scPharmaceuticals Inc. (SCPH) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    scPharmaceuticals Inc.

    NASDAQ: SCPH · Real-Time Price · USD
    5.58
    0.01 (0.18%)
    At close: Sep 08, 2025, 3:59 PM
    5.58
    -0.09%
    After-hours: Sep 08, 2025, 05:40 PM EDT

    scPharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 36.33M 13.59M n/a n/a
    Cost of Revenue
    		 11.36M 3.81M 468K 438K
    Gross Profit
    		 24.97M 9.78M -468K -438K
    Operating Income
    		 -64.78M -55.4M -36.16M -25.82M
    Interest Income
    		 3.44M 5.1M 1.2M 49K
    Pretax Income
    		 -85.15M -54.81M -36.84M -28.03M
    Net Income
    		 -85.15M -54.81M -36.84M -28.03M
    Selling & General & Admin
    		 77.65M 53.37M 20.62M 9.78M
    Research & Development
    		 12.1M 11.81M 15.53M 16.04M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 89.75M 65.18M 36.16M 25.82M
    Interest Expense
    		 7.57M 8.12M 3.3M 2.58M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 101.11M 68.99M 36.16M 25.82M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 44.52M 38.51M 28.36M 27.35M
    Shares Outstanding (Diluted)
    		 44.52M 38.51M 28.36M 27.35M
    EPS (Basic)
    		 -1.91 -1.42 -1.3 -1.02
    EPS (Diluted)
    		 -1.91 -1.42 -1.3 -1.02
    EBITDA
    		 -77.43M -46.06M -33.07M -25.02M
    EBIT
    		 -77.58M -46.69M -33.54M -25.46M
    Depreciation & Amortization
    		 148K 626K 468K 438K

    Add to Watchlist